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Prior to the COVID-19 pandemic, opioid use disorder posed its own endemic, with 115 people 
dying of an opioid overdose every day in the U.S.,1 becoming the most common cause of 
accidental death.2,3 With only 10-14% of patients with opioid use disorder (OUD) receiving 
treatment, there is a great need for increased access to care.4 Buprenorphine-naloxone (B/N) 
has proven to be an evidence-based medication for the treatment of OUD (MOUD)5-7 and since 
it can be prescribed in a primary care setting, unlike methadone, it can potentially increase 
access to treatment.  
 
During the COVID-19 pandemic, patients with OUD face additional challenges in accessing 
treatment with B/N in a safe way that minimizes exposure to COVID-19. Telehealth services that 
utilize audio and video phone technologies offer a venue for delivering addiction treatment to 
patients while eliminating person-to-person contact associated with travel and patient-provider 
encounters. 
 
Bicycle Health (BH) launched in January 2019 as a telehealth company with a goal of providing 
B/N for opioid dependent patients across California using a combination of in-person and virtual, 
telehealth visits. Comprised of family medicine physicians, physician assistants, nurse 
practitioners, health coaches, and psychologists, BH uses a team-based approach to support 
patients struggling with OUD. Prior to the COVID-era, BH was enrolling an average of 5 new 
patients/week. With the COVID-19 outbreak, demand rapidly increased to 10 new 
patients/week. Patients in remote and rural areas, those looking to minimize risk of community 
exposure to COVID-19, and those no longer able to procure opioids “off the street” due to “stay-
at home” orders and the restrictions on border crossings and hence suffering from opioid 
withdrawal, were looking for telehealth options for OUD treatment. To meet the increasing 
demand of treating patients with OUD in the COVID-19 era, BH was forced to both re-evaluate 
the evidence and new COVID-19 related guidelines that support decision points of delivering 
telehealth based services.  
 
In this case report, we share what BH learned, reviewing prior evidence and new COVID-19 
updates and highlight potential applications to guide frontline family medicine providers in 









Though limited by study number, several studies have suggested that compared to participants 
traveling for in-person treatment, telehealth visits may be associated with treatment retention8 
and may increase access to MOUD, particularly among patients in underserved and remote 
rural areas.9 
  
This article is a preprint and has not been peer reviewed. It reports new medical research or thought that 
has yet to be evaluated and so should not be used to guide clinical practice.  
 
Copyright © 2020 by Randi Sokol, Ankit Gupta, Sarah Powers, Liza Hoffman, and Julio Meza. Posted on 
Annals of Family Medicine COVID-19 Collection courtesy of Randi Sokol, Ankit Gupta, Sarah Powers, 




New COVID-19-related guidelines: 
 
The American Society of Addiction Medicine (ASAM) has recommended use of telehealth visits 
(in the form of audio or video phone calls) during the COVID-era. Federal and state regulators 
have made this possible by relaxing regulations: On January 31, 2020, the Secretary of the 
Department of Health and Human Services issued a public health emergency that created an 
exception to allow telehealth visits to occur without an in-person evaluation; on March 6, 2020, 
Medicare authorized reimbursement for telehealth services; on March 15,2020, health care 
providers were enabled to use non-HIPAA compliant telemedicine applications, such as 
FaceTime or Skype, without HHS-associated penalties. Finally, providers were authorized to 
prescribe B/N across state lines without obtaining additional DEA registration in the state where 
the medication is being dispensed. 
 
Bicycle Health’s response: 
 
To meet increased demand for enrollment and to decrease wait time, BH converted all new 
intake appointments (which were previously conducted as in-person appointments) to telehealth 
appointments and offered same or next-day appointments to increase timely access to care. 
 




While little evidence guides the duration of prescribing, prior to COVID-19, the Substance Abuse 
and Mental Health Services Administration (SAMHSA) 10 recommends weekly appointments 
during early treatment. Many clinicians subsequently space patients out to twice monthly and 
then monthly prescriptions once patients demonstrate greater stability. 
 
New COVID-19-related guidelines: 
 
ASAM recommends and the Drug Enforcement Administration (DEA) has enabled the 
prescribing of B/N via e- prescriptions, given its safety profile and that the benefits for providing 
B/N outweigh the risks of patients not receiving it and subsequently relapsing and overdosing.11 
In the era of COVID-19, providing longer duration of prescriptions is recommended to minimize 
community exposure associated with retrieving prescriptions from pharmacies. The Centers for 
Disease Control recommends that patients maintain a 2-week supply of all medications as part 
of a “household plan of action in case of illness in the household or disruption of daily 
activities”12 due to COVID-19. While providers may be concerned about the possibility of 
diversion with longer B/N prescriptions, the rate of this is much lower than that of other opioid 
agonists13 and most diverted B/N is used for self-treating opioid withdrawal rather than 
achieving euphoria.14  
 
For patients who are not stable or those without access to telephones (such as homeless 
patients), the benefits of providing shorter prescriptions and in-person visits may outweigh risks 
associated with COVID exposure; however, this must be tailored to the individual’s risk for a 
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COVID-19 infection. In particular, those patients at highest risk should minimize community 
exposure, including those 65 years or older and those with chronic medical conditions including 
lung disease, heart disease, immunocompromised and morbidity obese (BMI >40).  
 
Bicycle Health’s response: 
 
For new patients going through B/N induction, BH increased touchpoints through more 
telehealth visits and produced a simplified home induction guide to promote consistency in the 
home induction process. After reaching maintenance dose (usually about 1 week after 
induction), BH then spaced out stable patients to receive 2-week to 4-week-long B/N 
prescriptions.  
 




There is no agreed upon standard regarding the frequency or duration of testing, though 
gathering a baseline drug screen prior to initiation of B/N and some form of continued drug 
monitoring for overall compliance is recommended.15-17 Additionally, the use of random 
(compared to scheduled) drug screens has shown significant reductions in illicit drug use and is 
recommended as a best practice.18 It is recommended to set the frequency of testing higher at 
the start of treatment, when patients are known to more frequently engage in continued drug 
use.17 
New COVID-19-related guidelines: 
 
In general, ASAM recommends avoiding urine drug testing in the era of COVID, given the 
harms associated with community exposure for patients traveling to and presenting at health 
care facilities and for staff who collect urine samples with limited personal protective equipment. 
Patients who might benefit from urine drug testing are those for whom there is suspected 
diversion, intoxication, overdose, or very unstable OUD. Though, clinicians can generally take 
other strategies to support patients, such as increasing the frequency of telehealth visits, 
providing daily virtual observed self-administration of B/N, leveraging family members/loved 
ones, and reducing the amount of B/N prescribed at once. As a general rule, any test that will 
not change a patient’s management should be avoided. 
 
Bicycle Health’s response: 
 
Consistent with ASAM’s recommendations,18 BH uses toxicology testing to hold patients 
accountable and to augment their care when unexpected results are detected, thus supporting 
their recovery rather than using testing for putative purposes (such as discontinuing or tapering 
of B/N prescriptions); however, these test are performed and interpreted without the patient 
leaving their house: BH ships urine cups to the patients, the patient collects a sample during 
their televisit, and the results are viewed via video (with a temperature indicator confirming 
authenticity). If the test is not completed during the appointment, providers will not fill the B/N 
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prescription without a photo confirmation of the test results. In the future, BH plans to provide 
saliva tests to further enhance compliance. 
 




While behavioral approaches for managing OUD are encouraged, previous research has 
demonstrated that individual counseling does not have a consistent impact above high-quality 
standardized medication management approaches alone.19 
 
New COVID-19-related guidelines: 
 
In the COVID-19 era, the associated stress and anxiety and social isolation may be a trigger for 
patients struggling with OUD, and they likely would benefit from enhanced mental health 
support. However, lack of access to individual or group-based therapy should not preclude 
prescribing B/N. ASAM guidelines recommend that B/N providers: do not mandate participation 
in counseling (virtual or in-person) in order to receive B/N, convert therapeutic support to virtual 
platforms when possible, and if conducting in-person group visits, limit these to 10 individuals or 
less in a large room where patients can engage in social distancing (ie spaced out 6 feet apart). 
 
Bicycle Health’s response: 
 
To decrease social isolation and increase access to behavioral support, in addition to individual 
psychotherapeutic support previously offered, BH opened free virtual group visits facilitated by a 
trained behavioral health provider not only to BH patients but also anyone struggling with OUD. 





This case example from Bicycle Health illustrates practical application of providing MOUD with 
B/N in the COVID-19 era. Understanding the evidence and current COVID-19-related guidelines 
can help front line primary care providers employ new approaches that support patients by 
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